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Summary Cell survival was investigated in an intraocular retinoblastoma-like tumour 30min to 48h after
photodynamic therapy. The survival of the cells was assessed by an in vivo to in vitro colony forming assay,
estimated by either the plating efficiency of the treated tumour cells compared to non-treated cells or the
number of clonogenic cells per mg excised tumour. Curves showing cell survival as a function of the time
between light irradiation and excision of the intraocular tumours were biphasic. This suggests more than one
PDT tissue destruction mechanism in vivo (i.e. an early direct cell damage plus a subsequent late damage
occurring in the tumour tissue left in situ after treatment). The delayed mechanism may be due to changes in
the environment of the tumours probably caused by vascular damage. Tumour cells sensitised by Photofrin II
in vivo and excised from the eyes were damaged by light when irradiated in vitro and this was dependent on
the light energy dose. This showed that cellular Photofrin II uptake in the eye tumours was sufficient for
direct cell damage and thus supports the suggestion that direct and indirect tumour destruction occurs in this
eye tumour after photodynamic therapy.
Numerous experimental and clinical studies have resulted
from the interest in photodynamic therapy (PDT) as a
selective therapeutic modality in the management of cancer.
The principle of the treatment involves the combined actions
of three agents, i.e. haematoporphyrin derivatives, visible
light and oxygen, each of which are relatively non-toxic, but
combined together develop severe oxidative damage to
surrounding biological substrates (Moan, 1986; Dougherty,
1987).
A number of PDT studies on experimental eye tumours in
animals or retinoblastomas and choroidal melanomas in
humans have been reported in order to evaluate the
possibility of using PDT for management of intraocular
tumours (Bruce, 1984; Franken et al., 1985; Gomer et al.,
1985; Murphree et al., 1987; Ohnishy et al., 1986; Sery et al.,
1987; Winther et al., 1988). The advantage of PDT in this
approach is that it is possible to focus the light directly
through the pupils and onto the visible tumour surfaces.
At the present time histopathological intraocular tumour
damage, significant growth delay and tumour cure have been
demonstrated in retinoblastomas following PDT (Winther &
Ehlers, 1988; Horsman & Winther, 1989). However, tumour
recurrences also have been reported, indicating that a more
basic knowledge of the mechanism of PDT is mandatory in
order to improve the anti-tumour effect (Winther &
Overgaard, 1989).
The aim of the current study has thus been to describe the
PDT anti-tumour effect by characterisation of the kinetics of
cell damage following treatment in vivo. This paper focuses
on the occurrence of very early cell damage as well as effects
appearing later during the first two days after treatment.
Materials and methods
Retinoblastoma-like tumour model
The retinoblastoma-like cell line, EXP-5 (Kobayashi et al.,
1982) was used for producing intraocular tumours. Cells
were inoculated into the vitreous body of 6-13-day-old
inbred F 344 rats producing solid tumours, which are
supplied with blood vessels from the retina. The in vivo and
in vitro growth characteristics, histopathology, cytogenetics
and flow cytometry have been previously described (Winther,
1986; Winther et al., 1987).
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Haematoporphyrin derivative
The purified haematoporphyrin derivative, designated
Photofrin II (Photomedica, NJ, USA) was used for all
experiments. It was stored in darkness at -20°C until use.
After thawing the drug was diluted in saline and injected
intraperitoneally into animals, 24h before light irradiation.
Light irradiation and light dosimetry
In vivo The rats were anaesthetised by pentobarbital and
the pupil was dilated by one drop of tropicamid 1% before
light irradiation.
The tumours were irradiated by a 50mW helium-neon
laser (NEC, Japan) delivering light with a wavelength of
632.8nm. The laser beam was expanded by a -2 diopter
lens 26cm in front of the eye allowing an area of 0.6cm2 of
the eye to be irradiated, which resulted in an apparently
homogeneous light spot. The energy of the laser was
measured by a laser powermeter (Phir Laser Power monitor,
Ophir Optica Ltd, Jerusalem, Israel). The fluence rate on the
cornea was 50mWcm-2 giving a fluence of 3JCcm-2min-1.
The tumours were exposed to light either in vivo before
excision of the tumours or in tissue culture flasks after
plating.
In vitro Tissue culture flasks containing retinoblastoma-like
cells were light irradiated in a waterbath at 26-30'C by three
3,000W linear xenon flash lamps filtered by acrylic cut-off-
filters passing light in the range of 600-700nm. A dispersing
fat emulsion was added to the water to obtain an approxi-
mately homogeneous light irradiation (Bjerring et al., 1987).
The light energy was measured on the bottom of the flasks
by a high precision photometer with a cosine correction
(Bruel & Kjer, Copenhagen, Denmark). The fluence rate was
29mWcm-2, giving a fluence of 1.74Jcm-2 min- 1.
In vivo to in vitro colony forming assay The tumour size
was assessed by a stereoscopic microscope (Winther, 1986).
Tumours covering more than half of the retinae were used
for experiments. The Photofrin II was injected intraperi-
toneally 24h before light irradiation. The animals were
anaesthetised with pentobarbital before enucleation. The
globes were bisected under a microscope and all visible
tumour tissue was removed. Excised tumour was weighed
and generally found to be between 50-120mg. A single cell
suspension was prepared from all the removed tumour mass
without the use of enzymes by propagating the tissue
through needles of gradually reduced diameter.
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The total number of morphologically intact cells was
counted (i.e. cells having an intact and smooth outline with a
bright halo) for calculation of the plating efficiencies (PE).
Cell viability was primarily assessed by the exclusion of
trypan blue dye so that the concentration of cells in
suspension could be adjusted in order to produce 75-200
colonies per flask. Cell damage according to the trypan blue
exclusion test increased according to the treatment and
typically varied between 5-10% in non-treated tumours and
up to 90-95% in tumours treated with 5 or 10mg Photofrin
II and left in situ for 48h.
All tumour cells were diluted in a known amount of
RPMI 1640 tissue culture medium supplemented with 15%
fetal calf serum and containing O.1mgml-l streptomycin,
100,000 IUml-1 penicillin and 2 x I0 feeder cells (heavily
irradiated retinoblastoma-like cells) as previously described
(Winther, 1989). The cells were incubated in 5% CO2 and
95% air at 37°C for 9-11 days. Colonies were then fixed on
the bottom of the flasks with methanol and stained with
toluidine blue. Those colonies containing more than
approximately 50 cells were counted using a microscope. The
PE of non-treated tumour cells (i.e. the percentage of the
total number of plated cells forming colonies after explanting
into the tissue culture flasks) varied from 10 to 40% in the
present experiments.
Evaluation of results
In vivo to in vitro colony forming assay The therapeutic
response was assessed from the relative plating efficiency, i.e.
100 x PEtreated/PEuntreated (Figure 1) and from the relative
number of clonogenic cells per mg tumour tissue (Figure 2).
The relative number of clonogenic cells per mg tumour tissue
was the number of cells in treated tumours compared to the
number in non-treated controls. Clonogenicity in each
tumour was calculated from the number of colonies counted
in 3-9 flasks. Each point on the curves represents the mean
of 8-14 tumours. Logarithms of the observed number of
clonogenic cells showed a normal distribution. The
logarithmic mean of each group was tested by Student's t
test. Table I shows the total number of clonogenic cells per
mg tumour tissue in the treated eyes.
In vitro The PDT effect on tumour cells sensitised by
Photofrin II in vivo followed by light irradiation in vitro in
the culture flasks was described in terms of the relative
plating efficiency as defined above. The PDT sensitivity was
described by Do from the survival curves (i.e. the light
energy dose required for inactivation of I -l/e of the cells).
All in vitro experiments were performed at least three times
on different days. Each data point was calculated from 3-9
flasks in each experiment.
Results
The cell survival of intraocular tumours assessed by an in
vivo to in vitro assay at variable time after different
treatment doses and expressed as relative PE is shown in
Figure 1. The survival curves for 5 and 10mgkg- 1 Photofrin
II appeared to have a biphasic pattern as a function of the
time the tumours were left in the eyes after treatment, with
the slopes being steeper in the first 30min.
The data of Figure 1 were also expressed as the number of
relative clonogenic cells per mg treated tumour in Figure 2.
These results also demonstrated a biphasic curve of cell
survival similar to the patterns shown in Figure 1. The
curves declined rapidly, and a statistically significant
decrease was shown 30min after the light irradiation for the
groups treated with either 10 or 5mgkg-1 Photofrin II
(P<0.001). A borderline statistical significance was also
demonstrated in animals treated with 2.5mgkg 1 +90Jcm-2
(P=0.07). The mean and the range of the total number of
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Figure 1 Relative plating efficiency in PDT treated tumours
compared to non-treated tumours. Each data point represents
the mean of 8-14 tumours. Bars are s.e. and were deleted from
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Figure 2 Percentage of clonogenic cells per mg tumour tissue in
PDT treated tumours compared to non-treated tumours. Each
data point represents the means of 8-14 tumours.
In order to investigate whether the retinoblastoma-like
cells sensitised with Photofrin II in vivo had taken up
sufficient drug for cellular damage, the animals were injected
with Photofrin II in vivo. The tumours were excised and
explanted in culture flasks 24h after drug administration.
Single cells were then exposed to light in the flasks. Survival
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Table I The total number of clonogenic cells per mg tumour tissue in the retino-
blastoma-like tumours 30min to 48h after PDT
Photofrin II Light O.Sh 4h 24h 48h
(mgkg-1) (Jcm-2) (cells) (cells) (cells) (cells)
10 45 1,471a 838 472 96
(481-5,916) (226-1,950) (0-4,898) (0-1,059)
5 90 1,823 1,268 422 112
(360-6,577) (141-3,681) (16-2,729) (0-671)
2.5 90 2,722 1,474 2,350 1,950
(410-7,798) (472-3,724) (395-6,603) (63-6,124)
2.5 270 - 500 -
(0-2,501)
0 0 4,761 -
(1,011-18,858)
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Figure 3 Survival of tumour cells sensitised to Photofrin II in
vivo 24h before excision and plating as single cells in tissue
culture flasks for colony growth. The cells were exposed to light
in vitro. The curves were fitted by linear regression analysis. Each
data point was calculated from 3-9 flasks and all experiments
were repeated on at least three different days. Bars are s.e. Do
was calculated to 20J cm 2 for 20 mgkg -1 Photofrin II,
30Jcm-2 for 10mgkg- 1 Photofrin II and 92Jcm-2 for
5mgkg-1 Photofrin II.
curves of the tumour cells from animals treated with 5, 10 or
20mgkg- 1 Photofrin II are shown in Figure 3. All three
curves were statistically different and indicated an increased
cellular Photofrin II concentration in vivo at large treatment
doses in the range of 5-20mgkg-1. The surviving fraction of
cells treated with 2.5mgkg-1 Photofrin II followed by a
light exposure of 69 Jcm-2 was 78% (data not shown),
suggesting a low cellular drug concentration in the cells 24h
after injection.
The survival curve patterns for the present cells sensitised
with Photofrin II in vivo were similar to those previously
reported following in vitro sensitisation with Photofrin II
using the same light irradiation equipment and fluence rate
(Winther, 1989).
Discussion
There is controversy as to the importance of direct cell
damage in the response of tumours to PDT. Henderson et
al. (1985) reported that early cell damage did not occur in
subcutaneously growing experimental mice tumours (EMT-6
and RIF-1 tumours) assessed by an in vivo to in vitro
clonogenic assay. The results from that study combined with
several studies on vascular damage, haemorrhagic necrosis
and blood flow changes after PDT (Bugelski et al., 1981;
Selman et al., 1984; Berenbaum et al., 1986; Star et al., 1986;
Nelson et al., 1987) have consequently been the fundamental
basis for regarding vascular damage as the main mechanism
for PDT damage in vivo.
However, our current investigation, also using the in vivo
to in vitro assay procedure, demonstrated biphasic decline in
cell survival in the intraocular tumours as a function of time
after the light irradiation. This suggests the involvement of
more than one mechanism, one appearing early after
treatment and the other later. The early cell damage
occurring within 30min after light irradiation resulted in a
survival level of 30-57% of the total numbers of cells per mg
tumour tissue while the late effect inactivated the cells down
to the 1% survival level (Table I).
In the current intraocular tumour, PDT has previously
been shown to damage the vascular system and to decrease
blood flow to about 25% of the normal level 24h after light
administration (Winther & Ehlers, 1988; Horsman &
Winther, 1989). Tumour destruction by the late effect can
thus be explained by tissue anoxia in vivo. On the other
hand, the early cellular damage demonstrated within 30min
after the light irradiation could not be explained by tissue
anoxia because the blood flow in the treated tumours did
not start decreasing until at least 4h after the light
irradiation (Horsman & Winther, 1989).
The survival curves of retinoblastoma-like cells sensitised
by Photofrin II in the eyes followed by light irradiation in
vitro after the tumours were excised (Figure 3) confirmed
that the uptake of Photofrin II into cells was related to the
drug dose administered. Furthermore, the cellular uptake of
Photofrin II was sufficient for PDT cell destruction.
The results in the current study are thus indicative of
involvement of a direct cell damage mechanism following
PDT in vivo. The results showed the ratio between cell
survival assessed by the relative plating efficiencies and the
relative number of clonogenic cells/mg tumour was in the
range of 1.1-1.5 after 30min, increasing to 1.6-6.0 48h after
the light irradiation (Figures 1 and 2). This discrepancy can
be explained by a treatment-induced early cell loss resulting
in a lower cell yield and a consequently artificially increased
PE in the treated tumours.
Such differences between surviving fractions and number
of clonogenic cells have also been previously reported
following hyperthermia treatment of experimental tumours
(Marmor et al., 1977). This supports the hypothesis that
1no-
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PDT and local hyperthermia treatment have some similar
tissue destruction mechanisms (Waldow & Dougherty, 1984).
The difference in number of surviving cells between non-
treated tumours and tumours 30min after treatment was
more than 50% when 5 or 10mgkg-1 Photofrin II was
administered.
This was conflicting data compared to the lack of early
cell damage in the experimental mice tumours reported by
Henderson et al. (1985). Such differences are difficult to
explain because in both studies the tumours were treated
with similar external light irradiation and Photofrin II doses.
However, the discrepancies may be due to light attenuation
passing through the skin, which did not occur passing
through the transparent cornea and lens. This suggests that
the retinoblastoma-like cells received a relatively higher
energy dose than the subcutaneous tumours. The diverging
results may also be explained by differences in cellular
Photofrin II uptake due to varying degrees of tumour
vascularity. This is favoured by previously reported obser-
vations of higher concentration of tritium-labelled haemato-
porphyrin derivatives close to tumour blood vessels and a
decline in the concentration at large distances from the
vessels (Bugelski et al., 1981). A more efficient PDT tumour
response may then hypothetically be obtained by modified
photosensitisers which allow a more homogeneous tissue
distribution and/or a higher degree of cellular uptake.
In conclusion, the anti-tumour effect of PDT in the
present intraocular tumour consists of an early direct cell
inactivation plus a secondary tissue damage due to changes
in the tumour environment which probably is due to
vascular damage. Nevertheless, it is important to emphasise
that conclusive evidence of anoxic tissue damage following
PDT has not been presented so far.
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